Published in Biotech Law Weekly, September 2nd, 2005
The net loss in the second quarter of 2005 was $14.4 million or $0.61 per fully diluted common share. Excluding an $11.8 million ($0.49 per common share) charge for settlement of the shareholder class action lawsuit and a $902,000 ($0.04 per common share) noncash charge for the change in the value of the derivative related to the company's 6% convertible preferred stock, the adjusted net loss for the second quarter of 2005 was $1.7 million or $0.08 per fully diluted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.